<DOC>
	<DOCNO>NCT00109538</DOCNO>
	<brief_summary>The purpose study assess benefit lonafarnib ( versus placebo ) patient myelodysplastic syndrome ( MDS ) chronic myelomonocytic leukemia ( CMML ) . Benefit measured achievement platelet transfusion independence least 8-consecutive week , without simultaneous worsen hemoglobin and/or need red blood cell ( RBC ) transfusion . Additional endpoint hematologic response ( include complete remission , partial remission , hematologic improvement ) , number RBC transfusion , bleed event , infection safety .</brief_summary>
	<brief_title>Study Lonafarnib Versus Placebo Subjects With Either Myelodysplastic Syndrome ( MDS ) Chronic Myelomonocytic Leukemia ( CMML ) ( Study P02978AM3 ) ( TERMINATED )</brief_title>
	<detailed_description />
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Myelodysplastic Syndromes</mesh_term>
	<mesh_term>Preleukemia</mesh_term>
	<mesh_term>Leukemia , Myelomonocytic , Acute</mesh_term>
	<mesh_term>Leukemia , Myelomonocytic , Chronic</mesh_term>
	<criteria>Confirmed MDS ( RA , RARS , RAEB , RAEBT ) CMML accord FAB classification . Platelet transfusion dependence ( require 1 8 platelet transfusion event every 4 week period ( Day 84 Day 57 , Day 56 Day 29 , Day 28 Day 1 ) 8week retrospective 4week prospective screening period ) . The individual number platelet transfusion event three 4weekly period ( Day 84 Day 57 ; Day 56 Day 29 ; Day 28 Day 1 ) must differ great 2 average number platelet transfusion event 12 week screening period . If subject RBC transfusion dependent , number RBC transfusion event three 4weekly period ( Days 84 57 ; Day 56 Day 29 Day 28 Day 1 ) must differ 2 average number RBC transfusion event 12 week screening period . ECOG PS 02 . Subjects chemotherapy/radiotherapyassociated secondary MDS . &lt; 12 Weeks ( prior Day1 Randomization ) investigational drug use , chemotherapy , radiotherapy , immunotherapy treatment MDS/CMML best supportive care . Hx bonemarrow peripheral stemcell transplantation treatment donor lymphocyte infusion . Hx AML . Known hx immune thrombocytopenic purpura . Marked baseline prolongation QTc interval , CTCAE Grade &gt; =1 . Use ketokonazole within 72 hour prior study drug administration .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2015</verification_date>
	<keyword>Lonafarnib</keyword>
</DOC>